Steven L Pomerantz

20170210799, Jul 27, 2017

Jan 19, 2017

15/409630

- Horsham PA, US
Eric T. BALDWIN - Upper Holland PA, US
Benjamin HARMAN - Oaklyn NJ, US
Rosa M.F. CARDOSO - North Wales PA, US
Ricardo ATTAR - Lawrenceville NJ, US
Francois GAUDET - Princeton NJ, US
Yingzhe LI - Dresher PA, US
Jinquan LUO - Malvern PA, US
Ronan MCDAID - Eagleville PA, US
Steven C. POMERANTZ - Huntingdon Valley PA, US
Susan H. TAM - Garnet Valley PA, US
Alexey TEPLYAKOV - Phoenixville PA, US
Sheng-Jiun WU - Broomall PA, US

C07K 16/28

Provided herein are isolated antibodies that immunospecifically bind to ROR1, bispecific antibodies comprising an antigen-binding site that immunospecifically binds to ROR1 and an antigen-binding site that immunospecifically binds to CD3, and methods of using the same.

20160068605, Mar 10, 2016

Sep 3, 2015

14/844194

- Beerse, BE
Francois Gaudet - Princeton NJ, US
Ricardo Attar - Lawrenceville NJ, US
Benjamin C. Harman - Oaklyn NJ, US
Yingzhe Li - Dresher PA, US
Jinquan Luo - Malvern PA, US
Ronan McDaid - Eagleville PA, US
Steven C. Pomerantz - Huntingdon Valley PA, US
Susan H. Tam - Garnet Valley PA, US
Alexey Teplyakov - Phoenixville PA, US
John Wheeler - Downingtown PA, US
Sheng-Jiun Wu - Broomall PA, US

JANSSEN PHARMACEUTICA NV - Belgium

C07K 16/28

Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.